In an early-phase study, BCMA-targeted CAR-T therapy anito-cel generated responses in all 38 treated participants with relapsed or refractory multiple myeloma. The report described a favorable safety profile alongside durable long-term benefit signals. The trial results are framed as a strong initial efficacy readout for anito-cel, a category of therapies competing on response depth and durability while managing CAR-T-associated toxicities. Because Phase 1 programs typically enroll smaller cohorts with heterogeneous prior lines, the industry will look to subsequent studies to confirm consistency of benefit and to define patient subgroups most likely to achieve durable remissions. For biotech and investors, the all-comers response signal adds to the ongoing race to differentiate BCMA CAR-T constructs—especially on durability metrics.